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Abstract
Background: Atherogenic dyslipidemia (AD) is a common feature in persons with premature
coronary heart disease. While several linkage studies have been carried out to dissect the genetic
etiology of lipid levels, few have investigated the AD lipid triad comprising elevated serum
triglyceride, small low density lipoprotein (LDL) particles, and reduced high density lipoprotein
(HDL) cholesterol levels. Here we report the results of a whole-genome screen for AD using the
Framingham Heart Study population.
Results: Our analyses provide some evidence for linkage to AD on chromosomes 1q31, 3q29,
10q26, 14p12, 14q13, 16q24, 18p11, and 19q13.
Conclusion: AD susceptibility is modulated by multiple genes in different chromosomes. Our
study confirms results from other populations and suggests new areas of potential importance.
Background
Atherogenic dyslipidemia (AD) is characterized by three
lipid abnormalities: elevated serum triglyceride, small low
density lipoprotein (LDL) particles, and reduced high
density lipoprotein (HDL) cholesterol levels [1]. This
lipid triad occurs commonly in persons with premature
coronary heart disease [2]. Phenotypically, individuals
with AD tend to be obese, insulin resistant, and physically
inactive. Many investigators believe that AD is a part and
precursor of the metabolic syndrome, which also features
proinflammatory and prothrombotic states. Several link-
age studies have been carried out to dissect the genetic eti-
ology of lipid levels, both quantitatively and discretely.
However, there are few studies on AD, and the definitions
and study designs are inconsistent. In the present study,
we carried out a whole-genome screen with the aim of
identifying susceptibility genes for AD using the Framing-
ham Heart Study population.
Methods
Population
In this study, we used the Framingham Heart Study popu-
lation included in Problem 1 distributed to Genetic Anal-
ysis Workshop 13 participants. AD was operationally
defined as follows: 1) serum tryglyceride level at or above
the 90th percentile for age and sex; and 2) serum HDL cho-
lesterol at or below the 25th percentile for age and sex – as
given in NHANES III. Individuals with both high triglyc-
erides and low HDL as defined above were considered
"affected", while those with neither were considered
"unaffected". Affection status was "unknown" in the rest
(i.e., those with high triglycerides only or low HDL only,
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or whose lipid profiles were missing). LDL values were not
included in the data set.
Triglycerides and HDL data are available for only one year
(1971) in the original cohort (n = 394), and then only for
12 individuals. One individual was found to be affected
with the AD, 9 were unaffected, and 384 had unknown
status. Triglycerides and HDL data are available on all five
occasions (spanning two decades) in the offspring cohort
(n = 1308). Individuals were classified as having AD if
they fulfilled the operational criteria at any occasion (n =
119); conversely only individuals who were unaffected on
every occasion when data were available were categorized
as unaffected (n = 598) – the rest had unknown status (n
= 591).
Statistical analysis
Two-point parametric linkage analysis was performed
using VITESSE 2.0 [3]. Assuming the disease locus being at
a given map position, we calculated the likelihood of the
data, using a range of different dominant and recessive
transmission models, all yielding the same disease preva-
lence and parameterized as a single variable, the heterozy-
gote penetrance. The strategy of obtaining LOD scores
using alternative models of inheritance has been tested
successfully in several complex disorders [4,5]. To deter-
mine a set of likely regions for AD, nonparametric linkage
analysis (NPL) based on the Kong and Cox LOD score
derived from the Sall statistic of GENEHUNTER-Plus ver-
sion 2.0 [6] was used. Finally, two nonparametric affected
sib-pair analyses were performed. Maximum-likelihood
estimates of the proportions of sib pairs sharing 0, 1, or 2
alleles identically by descent (IBD) at marker loci were
estimated with the routine SIB-MLS of the software GAS
2.0 [7]. This nonparametric statistic is used to test for devi-
ations of these proportions from levels expected under the
null hypothesis of no linkage. We also performed Hase-
man-Elston regression [8] for all marker loci versus the
trait using full and half-sib relative pairs as implemented
in the software SIB-PAIR [9]. While this sib-pair linkage
method was originally developed for dealing with contin-
uous traits, it is also applicable to binary traits [10].
Results
There were 69 families with one affected member, 14 with
two, 5 with three, and 2 with four. In all, 11 markers
showed some evidence for linkage in parametric analysis
(see Table 1), but no marker showed two-point LOD
scores t 2.0 or p < 0.001. In the multi-point NPL analysis,
there was one Kong & Cox LOD score [6] above 2.0 on
14p (see Table 2). The six chromosomal areas with the
highest NPL scores were 3q29, 10q26, 14p12, 14q13,
18p11, and 19q13, but none reached significance (LOD
score > 3.5). Under the MLS affected sib-pair analyses,
seven markers on six chromosomes had two-point MLS
LOD scores = 1.20, which correspond to p < 0.01 (see
Table 3). The Haseman-Elston regression sib-pair analyses
revealed two suggestive markers with p < 0.05:
GGAA23C07 (1q31) and AFM031XA5 (16q24) (see Table
4).
Discussion
Our choice of an extreme phenotype based on lipid values
had a big impact on the number of families informative
for linkage analysis. From an original set of 90 families
with at least one affected individual, 21 were informative.
Due to this limited sample size, we carried out statistical
analyses using four alternative approaches that take
advantage of the different family structures that were
available: affected/unaffected parametric LOD score anal-
ysis, affected relative pair NPL analysis, affected sib-pair
MLS analysis, and the sib-pair Haseman-Elston regression
analysis. Some evidence for linkage to AD was found on
chromosomes 1q31, 3q29, 10q26, 14p12, 14q13, 16q24,
18p11, and 19q13. However, due to the limited statistical
power, these results should be interpreted with caution.
Several chromosomal areas showed some evidence of
linkage by more than one statistical method: 1p (paramet-
ric and MLS), 1q (parametric and Haseman-Elston), 14q
(NPL and MLS), 16q (parametric and Haseman-Elston),
and 19q (parametric and NPL). The latter, 19q13, is par-
ticularly important given that this is the area of the
ApoC2/ApoE/ApoC1/ApoC4 gene cluster. Several studies
have reported significant LOD scores for components of
the metabolic syndrome in this region. For example,
Elbein and Hasstedt [11] reported a LOD score of 3.16 for
triglycerides and of 2.76 for the triglycerides-to-HDL cho-
lesterol ratio in individuals with diabetes. Additionally,
the findings on 3q29 and 10q26 are in the vicinity of the
suggestive regions reported by Francke et al. [12] in Indo-
Mauritians with the metabolic syndrome (3q27, LOD
score = 2.13, p < 0.001; 10q23, LOD score = 2.06, p =
0.001) and of Vionnet et al. [13] in French whites with
type 2 diabetes (the markers on 10q26 were also reported
by Wiltshire et al. [14] in a UK population with type 2 dia-
betes). The 16q24 area overlaps with those reported by
Soro et al. [15] in Finnish families with low HDL and
Aouizerat et al. [16] in Dutch families with familial com-
bined hyperlipidemia.
Conclusion
Atherogenic dyslipidemia susceptibility is modulated by
multiple genes on different chromosomes. Our analyses
provide some evidence for linkage to atherogenic dyslipi-
demia on chromosomes 1q31, 3q29, 10q26, 14p12,
14q13, 16q24, 18p11, and 19q13. Our study confirms
results from other populations and suggests new areas of
potential importance.
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Table 1: Two-point parametric LOD scores.
Chromosome Marker (Location in cM) Lod Score (T) Model (Penetrance)
1 GGAT2A07 (45.33) 1.29 (0.10) Recessive (0.50)
1 GATA65H06 (72.59) 1.26 (0.00) Dominant (0.75)
1 GATA4H09 (218.46) 1.29 (0.15) Recessive (0.25)
1 GGAA23C07 (239.66) 1.58 (0.10) Dominant (0.85)
6 AFM242zg5 (146.06) 1.20 (0.10) Recessive (0.75)
6 GATA184A08 (166.39) 1.42 (0.10) Recessive (0.25)
8 GATA72C10 (37.04) 1.29 (0.00) Dominant (0.85)
10 GATA73E11 (59.03) 1.26 (0.10) Recessive (0.25)
12 GATA63D12 (95.03) 1.15 (0.00) Dominant (0.85)
16 AFM031XA5 (113.52) 1.95 (0.10) Recessive (0.85)
19 Mfd238 (100.61) 1.34 (0.05) Recessive (0.25)
Table 2: Multipoint NPL scores, their p-values, and Kong and Cox LOD scores.
Chromosome Location NPL (p-value) K&C LODA
3 246.82 1.95 (0.028) 1.10
10 179.05 2.36 (0.011) 1.95
14 0.0 2.10 (0.020) 2.01
14 37.92 1.87 (0.033) 0.66
18 31.42 1.71 (0.047) 0.90
19 111.74 1.712 (0.046) 0.74
ASee Kong and Cox [6].
Table 3: Two-point maximum LOD score (MLS).
Chromosome Marker (Location in cM) MLS
1 GGAT2A07 (45.33) 1.20
2 GATA69E12 (90.82) 1.20
3 GATA6G12 (209.41) 1.20
13 ATA26D07 (82.93) 1.20
14 ATA29G03 (40.68) 1.20
17 AFM044xg3 (116.86) 1.20
17 AFM217yd10 (126.46) 1.20
Table 4: Haseman-Elston regression sib-pair analysis.
Chromosome Marker (Location 
in cM)
Full Sibs Half Sibs t-Value Asymptotic p-
Value
1 GGAA23C07 
(218.46)
418 12 3.0 0.0013
16 AFM031XA5 (113.52) 402 12 2.5 0.0064
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